

Andres Cervantes

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9003256/andres-cervantes-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

185 papers	16,122 citations	46 h-index	126 g-index
242 ext. papers	20,507 ext. citations	6.8 avg, IF	6.37 L-index

#	Paper	IF	Citations
185	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.. <i>Cancer Chemotherapy and Pharmacology</i> , 2022 , 89, 499	3.5	1
184	Clinical management of metastatic colorectal cancer in the era of precision medicine.. <i>Ca-A Cancer Journal for Clinicians</i> , 2022 ,	220.7	8
183	Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences. <i>Clinical Cancer Research</i> , 2021 ,	12.9	14
182	Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. <i>Annals of Oncology</i> , 2021 , 32, 590-599	10.3	36
181	Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. <i>Cancer Cell</i> , 2021 , 39, 708-724.e11	24.3	34
180	Ten-year assessment of a cancer fast-track programme to connect primary care with oncology: reducing time from initial symptoms to diagnosis and treatment initiation. <i>ESMO Open</i> , 2021 , 6, 100148	6	1
179	Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2021 , 32, 801-805	10.3	49
178	Clinical Case Presentation and Discussion During ESO-ESMO Masterclass: a 10-Year Interactive Educational Experience. <i>Journal of Cancer Education</i> , 2021 , 36, 1124-1128	1.8	3
177	Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , 2021 , 22, 103-113	21.7	180
176	Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical assessment of a 10-year prospective national registry on behalf of the Spanish Rectal Cancer Project. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 276-284	3.6	6
175	ESO-ESMO Masterclass in Clinical Oncology: Analysis and Evaluation of the Learning Self-Assessment Test. <i>Journal of Cancer Education</i> , 2021 , 36, 556-560	1.8	4
174	Circulating tumor DNA analysis for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment in colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 11-11	2.2	8
173	Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. <i>Cancers</i> , 2021 , 13,	6.6	7
172	First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 1	7.4	1
171	Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. <i>Annals of Oncology</i> , 2021 , 32, 1496-1510	10.3	7
170	Radiomics and radiogenomics in head and neck squamous cell carcinoma: Potential contribution to patient management and challenges. <i>Cancer Treatment Reviews</i> , 2021 , 99, 102263	14.4	4
169	Reply to the letter to the editor: adjuvant nivolumab for the management of the pathological residual disease in esophageal or junctional tumors: a word of caution by P.K. Garg, R. Kumar and P. Dixit. <i>Annals of Oncology</i> , 2021 , 32, 1190-1191	10.3	

168	Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study. <i>British Journal of Cancer</i> , 2021 , 125, 1261-1269	8.7	4
167	Colorectal cancer survival: prevalence of psychosocial distress and unmet supportive care needs. <i>Supportive Care in Cancer</i> , 2021 , 1	3.9	0
166	Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data. <i>Clinical Colorectal Cancer</i> , 2021 , 20, 227-235	3.8	2
165	First-In-Human Phase I Study of a Next-Generation, Oral, TGF β Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2021 ,	12.9	2
164	Peritoneal invasion and metachronous peritoneal metastases after colon cancer surgery: The role of homogeneous, reliable assessment and confounders. <i>European Journal of Surgical Oncology</i> , 2021 , 47, 2697	3.6	
163	Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer. <i>Cancers</i> , 2020 , 12,	6.6	9
162	A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment. <i>Investigational New Drugs</i> , 2020 , 38, 1774-1783	4.3	4
161	Impact of perioperative transfusions and sepsis on long-term oncologic outcomes after curative colon cancer resection. A retrospective analysis of a prospective database. <i>Gastroenterology & Hepatology (English Edition)</i> , 2020 , 43, 63-72	0.1	
160	Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors. <i>Annals of Oncology</i> , 2020 , 31, 626-633	10.3	11
159	Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. <i>Annals of Oncology</i> , 2020 , 31, 334-351	10.3	64
158	EPDR1 up-regulation in human colorectal cancer is related to staging and favours cell proliferation and invasiveness. <i>Scientific Reports</i> , 2020 , 10, 3723	4.9	7
157	Efficacy and Determinants of Response to HER Kinase Inhibition in -Mutant Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020 , 10, 198-213	24.4	41
156	JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. <i>Annals of Oncology</i> , 2020 , 31, 861-872	10.3	43
155	The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target. <i>Cancer Treatment Reviews</i> , 2020 , 86, 102015	14.4	75
154	Personalized Medicine: Recent Progress in Cancer Therapy. <i>Cancers</i> , 2020 , 12,	6.6	39
153	Aurora kinases in ovarian cancer. <i>ESMO Open</i> , 2020 , 5, e000718	6	5
152	Short-course radiotherapy followed by chemotherapy before TME in locally advanced rectal cancer: The randomized RAPIDO trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4006-4006	2.2	67
151	Circulating tumor DNA to detect minimal residual disease, response to adjuvant therapy, and identify patients at high risk of recurrence in patients with stage I-III CRC.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4009-4009	2.2	3

150	Impact of perioperative transfusions and sepsis on long-term oncologic outcomes after curative colon cancer resection. A retrospective analysis of a prospective database. <i>Gastroenterology & Hepatology</i> , 2020 , 43, 63-72	0.9	1
149	Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors. <i>Current Topics in Medicinal Chemistry</i> , 2020 , 20, 1628-1639	3	1
148	A preclinical model for skin sensitization prediction of antineoplastic drugs.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e15643-e15643	2.2	
147	Mechanisms of skin toxicity of paclitaxel: An in vitro preclinical assessment.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e15511-e15511	2.2	0
146	The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper. <i>Radiotherapy and Oncology</i> , 2020 , 142, 6-16	5.3	8
145	Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer. <i>ESMO Open</i> , 2020 , 5, e000847	6	6
144	Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	7
143	Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre. <i>ESMO Open</i> , 2020 , 5, e000929	6	2
142	Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. <i>Annals of Oncology</i> , 2020 , 31, 1320-1335	10.3	121
141	Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. <i>British Journal of Cancer</i> , 2020 , 123, 1590-1598	8.7	17
140	How we treat metastatic colorectal cancer. <i>ESMO Open</i> , 2020 , 4, e000813	6	20
139	The McCaVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC). <i>Oncologist</i> , 2020 , 25, e451-e459	5.7	17
138	Changing the education paradigm in oncology: ESO masterclass, 17 years of continuous success. <i>Critical Reviews in Oncology/Hematology</i> , 2020 , 146, 102798	7	5
137	Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications. <i>ESMO Open</i> , 2019 , 4, e000476	6	15
136	Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer. <i>Annals of Oncology</i> , 2019 , 30, 1804-1812	10.3	64
135	Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019 , 30, 1558-1571	10.3	62
134	Analytical Validation of Multiplex Biomarker Assay to Stratify Colorectal Cancer into Molecular Subtypes. <i>Scientific Reports</i> , 2019 , 9, 7665	4.9	23
133	Molecular profile in Paraguayan colorectal cancer patients, towards to a precision medicine strategy. <i>Cancer Medicine</i> , 2019 , 8, 3120-3130	4.8	2

132	Improving tumour budding evaluation in colon cancer by extending the assessment area in colectomy specimens. <i>Histopathology</i> , 2019 , 75, 517-525	7.3	3
131	Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2019 , 25, 4888-4897	12.9	110
130	Towards precision oncology for HER2 blockade in gastroesophageal adenocarcinoma. <i>Annals of Oncology</i> , 2019 , 30, 1254-1264	10.3	11
129	Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , 2019 , 20, 849-861	21.7	201
128	Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2019 , 112, 12-19	7.5	5
127	Early Detection for Colorectal Cancer: ASCO Resource-Stratified Guideline. <i>Journal of Global Oncology</i> , 2019 , 5, 1-22	2.6	16
126	Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline. <i>Journal of Global Oncology</i> , 2019 , 5, 1-19	2.6	37
125	Context matters-consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials. <i>Annals of Oncology</i> , 2019 , 30, 520-527	10.3	47
124	Combination of KIR2DS4 and FcRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer. <i>Scientific Reports</i> , 2019 , 9, 2589	4.9	6
123	Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019 , 25, 3220-3228	12.9	99
122	The Medical Oncology resident mentor: situation and workload. <i>Clinical and Translational Oncology</i> , 2019 , 21, 304-313	3.6	4
121	A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019 , 178, 121-133	4.4	4
120	ZNF518B gene up-regulation promotes dissemination of tumour cells and is governed by epigenetic mechanisms in colorectal cancer. <i>Scientific Reports</i> , 2019 , 9, 9339	4.9	5
119	Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study. <i>European Journal of Cancer</i> , 2019 , 123, 146-154	7.5	29
118	Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty. <i>ESMO Open</i> , 2019 , 4, e000533	6	
117	Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer. <i>ESMO Open</i> , 2019 , 4, e000519	6	3
116	A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. <i>ESMO Open</i> , 2019 , 4, e000532	6	5
115	Prognostic Impact of pT Stage and Peritoneal Invasion in Locally Advanced Colon Cancer. <i>Diseases of the Colon and Rectum</i> , 2019 , 62, 684-693	3.1	16

114	Definition of the Rectum: An International, Expert-based Delphi Consensus. <i>Annals of Surgery</i> , 2019 , 270, 955-959	7.8	45
113	Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression. <i>Modern Pathology</i> , 2019 , 32, 306-313	9.8	16
112	Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer. <i>Gynecologic Oncology</i> , 2019 , 152, 53-60	4.9	26
111	NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in -Amplified Gastric Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 1639-1649	12.9	30
110	The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?. <i>Annals of Oncology</i> , 2018 , 29, 1099-1107	10.3	23
109	Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. <i>Annals of Oncology</i> , 2018 , 29, 44-70	10.3	260
108	Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. <i>Investigational New Drugs</i> , 2018 , 36, 848-859	4.3	31
107	The role of chemotherapy in localized and locally advanced rectal cancer: A systematic revision. <i>Cancer Treatment Reviews</i> , 2018 , 63, 156-171	14.4	26
106	European Society for Medical Oncology (ESMO) position paper on supportive and palliative care. <i>Annals of Oncology</i> , 2018 , 29, 36-43	10.3	120
105	Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers. <i>Future Oncology</i> , 2018 , 14, 1629-1645	3.6	14
104	Precision medicine in the adjuvant treatment of gastric cancer. <i>Lancet Oncology, The</i> , 2018 , 19, 583-584	21.7	14
103	Liquid biopsy: another tool towards tailored therapy in colorectal cancer. <i>Annals of Oncology</i> , 2018 , 29, 7-8	10.3	7
102	Preclinical models for precision oncology. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2018 , 1870, 239-246	11.2	22
101	Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis. <i>Gastroenterology Research and Practice</i> , 2018 , 2018, 2373868	2	19
100	The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios. <i>Cancer Treatment Reviews</i> , 2018 , 70, 1-8	14.4	84
99	Borderline resectable pancreatic cancer. Challenges and controversies. <i>Cancer Treatment Reviews</i> , 2018 , 68, 124-135	14.4	17
98	New localization and function of calpain-2 in nucleoli of colorectal cancer cells in ribosomal biogenesis: effect of KRAS status. <i>Oncotarget</i> , 2018 , 9, 9100-9113	3.3	3
97	Role of epigenetic factors in the selection of the alternative splicing isoforms of human in colorectal cancer cell lines. <i>Oncotarget</i> , 2018 , 9, 20578-20589	3.3	9

96	In the literature: October 2018. <i>ESMO Open</i> , 2018 , 3, e000447	6	
95	In the literature: December 2018. <i>ESMO Open</i> , 2018 , 3, e000468	6	
94	In the literature: August 2018. <i>ESMO Open</i> , 2018 , 3, e000427	6	
93	Training in communication of oncology clinicians: a position paper based on the third consensus meeting among European experts in 2018. <i>Annals of Oncology</i> , 2018 , 29, 2033-2036	10.3	13
92	Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer. <i>ESMO Open</i> , 2018 , 3, e000425	6	24
91	Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018 , 29, iv238-iv255	10.3	355
90	Integration of oncology and palliative care: a Lancet Oncology Commission. <i>Lancet Oncology</i> , 2018 , 19, e588-e653	21.7	230
89	Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 4380-4387	12.9	41
88	Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. <i>Annals of Oncology</i> , 2017 , 28, 1713-1729	10.3	454
87	A Phase Ib Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Cobimetinib and Duligotuzumab in Patients with Previously Treated Locally Advanced or Metastatic Cancers with Mutant KRAS. <i>Oncologist</i> , 2017 , 22, 1024-e89	5.7	15
86	Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity. <i>Clinical Cancer Research</i> , 2017 , 23, 5406-5415	12.9	24
85	In the literature: February 2017. <i>ESMO Open</i> , 2017 , 2, e000171	6	
84	In the literature: April 2017. <i>ESMO Open</i> , 2017 , 2, e000193	6	
83	Self-expanding metallic stent as a bridge to surgery in the treatment of left colon cancer obstruction: Cost-benefit analysis and oncologic results. <i>Cirugía Española</i> , 2017 , 95, 143-151	0.7	18
82	A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors. <i>Cancer Discovery</i> , 2017 , 7, 102-113	24.4	105
81	Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017 , 28, iv22-iv40	10.3	627
80	Final results of the McCaVE trial: A double-blind, randomized phase 2 study of vanucizumab (VAN) plus FOLFOX vs. bevacizumab (BEV) plus FOLFOX in patients (pts) with previously untreated metastatic colorectal carcinoma (mCRC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3539-3539	2.2	11
79	Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer. <i>PLoS ONE</i> , 2017 , 12, e0177331	3.7	23

78	mRNA expression profiles obtained from microdissected pancreatic cancer cells can predict patient survival. <i>Oncotarget</i> , 2017 , 8, 104796-104805	3.3	1
77	Sequence variation in mature microRNA-608 and benefit from neo-adjuvant treatment in locally advanced rectal cancer patients. <i>Carcinogenesis</i> , 2016 , 37, 852-7	4.6	13
76	Clinical implications of routine genomic mutation sequencing in PIK3CA/AKT1 and KRAS/NRAS/BRAF in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 160, 69-77	4.4	13
75	Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania. <i>European Journal of Cancer</i> , 2016 , 63, 110-7	7.5	20
74	First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors. <i>Clinical Cancer Research</i> , 2016 , 22, 877-85	12.9	43
73	Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016 , 12, 449-56	5.5	6
72	Reply to the letter to the editor QHow much evidence is nQin evidence-based guidelines?Q by Johnson et al. <i>Annals of Oncology</i> , 2016 , 27, 550-1	10.3	
71	Epigenetic changes in localized gastric cancer: the role of RUNX3 in tumor progression and the immune microenvironment. <i>Oncotarget</i> , 2016 , 7, 63424-63436	3.3	12
70	Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology. <i>Oncotarget</i> , 2016 , 7, 22543-55	3.3	9
69	Treatment sequence of synchronously (liver) metastasized colon cancer. <i>Digestive and Liver Disease</i> , 2016 , 48, 1119-23	3.3	12
68	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016 , 27, 1386-422	10.3	1683
67	Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). <i>ESMO Open</i> , 2016 , 1, e000107	6	8
66	In silico RNA-seq and experimental analyses reveal the differential expression and splicing of EPDR1 and ZNF518B genes in relation to KRAS mutations in colorectal cancer cells. <i>Oncology Reports</i> , 2016 , 36, 3627-3634	3.5	9
65	PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer. <i>Annals of Oncology</i> , 2016 , 27, 1557-65	10.3	47
64	Personalised Treatment in Gastric Cancer: Myth or Reality?. <i>Current Oncology Reports</i> , 2016 , 18, 41	6.3	11
63	The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona. <i>Digestive and Liver Disease</i> , 2016 , 48, 1283-1289	3.3	19
62	Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016 , 27, v38-v49	10.3	796
61	MassARRAY determination of somatic oncogenic mutations in solid tumors: Moving forward to personalized medicine. <i>Cancer Treatment Reviews</i> , 2016 , 49, 57-64	14.4	9

60	Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. <i>Lancet Oncology, The</i> , 2015 , 16, 928-36	21.7	475
59	Extending neoadjuvant chemotherapy in rectal cancer. <i>Lancet Oncology, The</i> , 2015 , 16, 880-1	21.7	1
58	Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial. <i>Annals of Oncology</i> , 2015 , 26, 1936-1941	10.3	18
57	FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study. <i>Gut</i> , 2015 , 64, 921-8	19.2	17
56	Primary paraesophageal Ewing sarcoma: an uncommon case report and literature review. <i>OncoTargets and Therapy</i> , 2015 , 8, 1053-9	4.4	4
55	EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is Dependent on KRAS Mutational Status in Colorectal Cancer Cells. <i>PLoS ONE</i> , 2015 , 10, e0130543	3.7	8
54	Deregulation of ARID1A, CDH1, cMET and PIK3CA and target-related microRNA expression in gastric cancer. <i>Oncotarget</i> , 2015 , 6, 26935-45	3.3	30
53	Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer. <i>British Journal of Cancer</i> , 2015 , 112, 1874-81	8.7	25
52	Abstract P6-12-02: Phase Ib dose-escalation study of an Akt inhibitor ipatasertib (Ipat) in combination with docetaxel (Doc) or paclitaxel (Pac) in patients (pts) with metastatic breast cancer (MBC) 2015 ,		3
51	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS3634-TPS3634	2.2	2
50	Prognostic effect of a single nucleotide polymorphism (SNP) in MIR608 in patients with high-risk locally advanced rectal cancer (LARC): Results of the EXPERT-C trial.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 581-581	2.2	1
49	GAIN-(C): Efficacy and safety analysis of imgatuzumab (GA201), a novel dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with FOLFIRI compared to cetuximab plus FOLFIRI in second-line KRAS exon 2 wild type (e2WT) or with FOLFIRI alone in mutated (e2MT) metastatic colorectal cancer (mCRC).. <i>Journal</i>	2.2	10
48	Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS789-TPS789	2.2	1
47	Unmet needs and challenges in gastric cancer: the way forward. <i>Cancer Treatment Reviews</i> , 2014 , 40, 692-700	14.4	135
46	EURECCA colorectal: multidisciplinary management: European consensus conference colon & rectum. <i>European Journal of Cancer</i> , 2014 , 50, 1.e1-1.e34	7.5	274
45	Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014 , 25 Suppl 3, iii1-9	10.3	702
44	Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. <i>European Journal of Surgical Oncology</i> , 2014 , 40, 1165-76	3.6	98
43	TP53 mutational status and cetuximab benefit in rectal cancer: 5-year results of the EXPERT-C trial. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	44

42	Exploring better strategies for EGFR antibodies in colon cancer. <i>Lancet Oncology, The</i> , 2014 , 15, 549-50	21.7	11
41	Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. <i>European Journal of Surgical Oncology</i> , 2014 , 40, 584-591	3.6	137
40	Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. <i>Radiotherapy and Oncology</i> , 2014 , 111, 330-9	5.3	116
39	Prognostic implications of the standardized study of resection margins in pancreatic cancers. <i>Cirugía Española</i> , 2014 , 92, 532-8	0.7	11
38	Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma. <i>European Journal of Cancer</i> , 2014 , 50, 496-505	7.5	24
37	Quality assurance in the treatment of colorectal cancer: the EURECCA initiative. <i>Annals of Oncology</i> , 2014 , 25, 1485-92	10.3	35
36	Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014 , 25 Suppl 3, iii10-20	10.3	112
35	Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Radiotherapy and Oncology</i> , 2014 , 110, 189-94	5.3	25
34	Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3568-3568	2.2	27
33	Panex: A pooled analysis of EXPERT and EXPERT-C, two trials of neoadjuvant chemotherapy (NACT) and chemoradiotherapy (CRT) in high-risk locally advanced rectal cancer (LARC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3575-3575	2.2	5
32	RAS mutations in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab (C) in MRI-defined, high-risk rectal cancer (RC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 489-489	2.2	2
31	Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, LBA387-LBA387	2.2	20
30	Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR treatment.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3551-3551	2.2	
29	Relationship of RAS and TP53 predictive value for cetuximab (C) benefit: Results of the EXPERT-C trial.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 447-447	2.2	
28	Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013 , 24 Suppl 6, vi81-8	10.3	345
27	Current questions for the treatment of advanced gastric cancer. <i>Cancer Treatment Reviews</i> , 2013 , 39, 60-7	14.4	133
26	Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2013 , 24 Suppl 6, vi64-72	10.3	580
25	Undergraduate training in oncology: an ESO continuing challenge for medical students. <i>Surgical Oncology</i> , 2012 , 21, 15-21	2.5	26

24	First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. <i>Oncologist</i> , 2012 , 17, 15-25	5.7	170
23	ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. <i>Annals of Oncology</i> , 2012 , 23, 2479-2516	10.3	984
22	Intracellular signalling via the AKT axis and downstream effectors is active and prognostically significant in cancer of unknown primary (CUP): a study of 100 CUP cases. <i>Annals of Oncology</i> , 2012 , 23, 2725-2730	10.3	13
21	Phase I pharmacokinetic/pharmacodynamic study of MLN8237, an investigational, oral, selective aurora a kinase inhibitor, in patients with advanced solid tumors. <i>Clinical Cancer Research</i> , 2012 , 18, 4764-74	12.9	119
20	Pathological evaluation of mesocolic resection quality and ex vivo methylene blue injection: what is the impact on lymph node harvest after colon resection for cancer?. <i>Diseases of the Colon and Rectum</i> , 2012 , 55, 197-204	3.1	16
19	A phase 3 trial of bevacizumab in ovarian cancer. <i>New England Journal of Medicine</i> , 2011 , 365, 2484-96	59.2	1454
18	Growth factor receptor-related therapy for gastric cancer. <i>European Journal of Cancer</i> , 2011 , 47 Suppl 3, S324-5	7.5	
17	Preoperative chemoradiation may not always be needed for patients with T3 and T2N+ rectal cancer. <i>Cancer</i> , 2011 , 117, 3118-25	6.4	76
16	Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. <i>Annals of Oncology</i> , 2010 , 21, 1537-1545	10.3	62
15	Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4706-13	2.2	789
14	Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment. <i>Annals of Oncology</i> , 2010 , 21 Suppl 5, v93-7	10.3	322
13	Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system. <i>Clinical and Translational Oncology</i> , 2009 , 11, 787-98	3.6	31
12	Progress in the multidisciplinary treatment of gastrointestinal cancer and the impact on clinical practice: perioperative management of rectal cancer. <i>Annals of Oncology</i> , 2008 , 19 Suppl 7, vii266-72	10.3	11
11	The treatment of advanced gastric cancer: current strategies and future perspectives. <i>Annals of Oncology</i> , 2008 , 19 Suppl 5, v103-7	10.3	67
10	Molecular biology of gastric cancer. <i>Clinical and Translational Oncology</i> , 2007 , 9, 208-15	3.6	40
9	Oncology for medical students: a European School of Oncology contribution to undergraduate cancer education. <i>Cancer Treatment Reviews</i> , 2007 , 33, 419-26	14.4	28
8	Emerging strategies in the treatment of advanced esophageal, gastroesophageal junction, and gastric cancer: the introduction of targeted therapies. <i>Targeted Oncology</i> , 2006 , 1, 23-33	5	1
7	A multimodality approach to localized rectal cancer. <i>Annals of Oncology</i> , 2006 , 17 Suppl 10, x129-34	10.3	9

6	Capecitabine as adjuvant treatment for stage III colon cancer. <i>New England Journal of Medicine</i> , 2005 , 352, 2696-704	59.2	958
5	Oncological emergencies. <i>Annals of Oncology</i> , 2004 , 15 Suppl 4, iv299-306	10.3	32
4	An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing Epidermal Growth Factor Receptor (EGFR). Preliminary results. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3512-3512	2.2	23
3	Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer. <i>Seminars in Oncology</i> , 1997 , 24, S15-40-S15-43	5.5	
2	A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). <i>Cancer</i> , 1995 , 76, 559-63	6.4	21
1	5-Fluorouracil, folinic acid, epidoxorubicin and cisplatin (FLEP) combination chemotherapy in advanced measurable gastric cancer. A phase II trial of the Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD). <i>Annals of Oncology</i> , 1993 , 4, 753-7	10.3	14